| Naftifine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Naftifine | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Naftifine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Naftifine | hsa00190 | Oxidative phosphorylation | 3.92E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
| Naftifine | hsa00220 | Arginine biosynthesis | 1.28E-03 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | |
| Naftifine | hsa00250 | Alanine, aspartate and glutamate metabolism | 1.97E-02 | 2 | P49448, P15104 | GLUD2, GLUL | More | |
| Naftifine | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
| Naftifine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Naftifine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Naftifine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Naftifine | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Naftifine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Naftifine | hsa00830 | Retinol metabolism | 2.17E-03 | 4 | P00325, P00352, Q9BPW9, O75911 | ADH1B, ALDH1A1, DHRS9, DHRS3 | More | |
| Naftifine | hsa00910 | Nitrogen metabolism | 1.97E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | |
| Naftifine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Naftifine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Naftifine | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
| Naftifine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Naftifine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Naftifine | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Naftifine | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | |
| Naftifine | hsa03020 | RNA polymerase | 4.49E-07 | 5 | P30876, P24928, P62487, Q9GZM3, P52435 | POLR2B, POLR2A, POLR2G, POLR2J2, POLR2J | More | |
| Naftifine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Naftifine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | |
| Naftifine | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | |
| Naftifine | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | |
| Naftifine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | |
| Naftifine | hsa04062 | Chemokine signaling pathway | 6.73E-03 | 9 | P25024, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P43250, Q08881 | CXCR1, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, GRK6, ITK | More | |
| Naftifine | hsa04064 | NF-kappa B signaling pathway | 3.53E-05 | 16 | Q13489, O00463, Q13546, P14778, P01584, Q04759, Q9UDY8, P07948, P06239, P63279, P24522, Q8NHW4, P09341, Q06643, Q9UNE0, Q9NQC7 | BIRC3, TRAF5, RIPK1, IL1R1, IL1B, PRKCQ, MALT1, LYN, LCK, UBE2I, GADD45A, CCL4L2, CXCL1, LTB, EDAR, CYLD | More | |
| Naftifine | hsa04071 | Sphingolipid signaling pathway | 6.08E-04 | 5 | P21453, Q9H228, P01375, Q13362, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, GAB2 | More | |
| Naftifine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Naftifine | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
| Naftifine | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Naftifine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Naftifine | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | |
| Naftifine | hsa04144 | Endocytosis | 1.67E-02 | 8 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, GIT2, SNX12 | More | |
| Naftifine | hsa04145 | Phagosome | 2.57E-02 | 4 | Q15080, P14598, Q13488, O60603 | NCF4, NCF1, TCIRG1, TLR2 | More | |
| Naftifine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | |
| Naftifine | hsa04151 | PI3K-Akt signaling pathway | 3.96E-02 | 8 | P43657, P09603, Q9GZP0, P63218, P50151, P13612, O15335, Q13751 | P2RY5, CSF1, PDGFD, GNG5, GNG10, ITGA4, CHAD, LAMB3 | More | |
| Naftifine | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
| Naftifine | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | |
| Naftifine | hsa04213 | Longevity regulating pathway - multiple species | 3.14E-03 | 5 | Q9Y4H2, Q08828, P51828, P0DMV8, Q13547 | IRS2, ADCY1, ADCY7, HSPA1A, HDAC1 | More | |
| Naftifine | hsa04217 | Necroptosis | 2.34E-05 | 13 | P01375, P01568, P48023, Q13489, Q13546, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | |
| Naftifine | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
| Naftifine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Naftifine | hsa04270 | Vascular smooth muscle contraction | 6.96E-03 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | |
| Naftifine | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
| Naftifine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Naftifine | hsa04512 | ECM-receptor interaction | 4.41E-02 | 3 | Q13751, P13612, O15335 | LAMB3, ITGA4, CHAD | More | |
| Naftifine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Naftifine | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Naftifine | hsa04612 | Antigen processing and presentation | 9.02E-05 | 8 | P13765, P01730, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, CD4, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Naftifine | hsa04613 | Neutrophil extracellular trap formation | 2.15E-05 | 11 | P11215, Q13547, P04908, Q93077, P58876, P62807, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Naftifine | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | |
| Naftifine | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
| Naftifine | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Naftifine | hsa04623 | Cytosolic DNA-sensing pathway | 7.14E-06 | 5 | P01584, P01568, Q13546, P25963, Q8NHW4 | IL1B, IFNA21, RIPK1, NFKBIA, CCL4L2 | More | |
| Naftifine | hsa04640 | Hematopoietic cell lineage | 2.49E-05 | 11 | P13612, P21926, P14778, P27930, P25063, P07766, P09693, P01732, P01730, P09564, P13765 | ITGA4, CD9, IL1R1, IL1R2, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB | More | |
| Naftifine | hsa04650 | Natural killer cell mediated cytotoxicity | 4.00E-07 | 13 | P16298, P50591, P01375, P06239, O60880, P20963, Q02750, Q13241, P26718, O14931, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, NCR3, KLRC2, KIR2DS5, KLRC1 | More | |
| Naftifine | hsa04657 | IL-17 signaling pathway | 2.10E-03 | 5 | P49841, P19875, P14780, P80188, P01375 | GSK3B, CXCL2, MMP9, LCN2, TNF | More | |
| Naftifine | hsa04658 | Th1 and Th2 cell differentiation | 2.44E-07 | 11 | Q04759, P07766, P20963, P09693, P01730, P06239, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, CD4, LCK, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | |
| Naftifine | hsa04659 | Th17 cell differentiation | 4.63E-06 | 11 | Q04759, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | |
| Naftifine | hsa04660 | T cell receptor signaling pathway | 8.91E-04 | 9 | Q04759, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239 | PRKCQ, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK | More | |
| Naftifine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Naftifine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Naftifine | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Naftifine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | |
| Naftifine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Naftifine | hsa04724 | Glutamatergic synapse | 9.51E-03 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | |
| Naftifine | hsa04727 | GABAergic synapse | 2.33E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
| Naftifine | hsa04730 | Long-term depression | 3.72E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | |
| Naftifine | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.01E-02 | 4 | P01584, Q08828, P51828, P0DP23 | IL1B, ADCY1, ADCY7, CALM1 | More | |
| Naftifine | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
| Naftifine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Naftifine | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | |
| Naftifine | hsa04915 | Estrogen signaling pathway | 3.17E-02 | 5 | Q08828, P51828, P0DMV8, P0DP23, Q15788 | ADCY1, ADCY7, HSPA1A, CALM1, NCOA1 | More | |
| Naftifine | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
| Naftifine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Naftifine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Naftifine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Naftifine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Naftifine | hsa04932 | Non-alcoholic fatty liver disease | 7.01E-05 | 11 | P01375, P49841, O43521, P48023, O75460, P01584, P13073, P12074, Q16718, O95298, O14521 | TNF, GSK3B, BCL2L11, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFA5, NDUFC2, SDHD | More | |
| Naftifine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Naftifine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Naftifine | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Naftifine | hsa04970 | Salivary secretion | 2.43E-03 | 6 | P07550, Q08828, P51828, P22694, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, CALM1, CAMP | More | |
| Naftifine | hsa04972 | Pancreatic secretion | 1.31E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | |
| Naftifine | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | |
| Naftifine | hsa04976 | Bile secretion | 1.90E-04 | 6 | O43315, Q08828, P51828, P22694, P08183, Q14032 | AQP9, ADCY1, ADCY7, PRKACB, ABCB1, BAAT | More | |
| Naftifine | hsa05010 | Alzheimer disease | 4.39E-02 | 6 | O15399, Q9NZJ5, Q13564, Q71U36, P09603, P21796 | GRIN2D, EIF2AK3, APPBP1, TUBA1A, CSF1, VDAC1 | More | |
| Naftifine | hsa05016 | Huntington disease | 1.00E-04 | 12 | O95298, P13073, P12074, Q9GZM3, P24928, P30876, P62487, P52435, Q9NYC9, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2J2, POLR2A, POLR2B, POLR2G, POLR2J, DNAH9, ERN1, PSMB4, PSMD12 | More | |
| Naftifine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | |
| Naftifine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
| Naftifine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
| Naftifine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Naftifine | hsa05032 | Morphine addiction | 1.34E-02 | 4 | P63218, P50151, Q07343, P43250 | GNG5, GNG10, PDE4B, GRK6 | More | |
| Naftifine | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Naftifine | hsa05100 | Bacterial invasion of epithelial cells | 4.50E-02 | 1 | Q92529 | SHC3 | More | |
| Naftifine | hsa05132 | Salmonella infection | 9.85E-03 | 4 | Q13546, Q13489, O60282, P68371 | RIPK1, BIRC3, KIF5C, TUBB2C | More | |
| Naftifine | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Naftifine | hsa05134 | Legionellosis | 2.82E-02 | 3 | P01584, Q9NR31, P0DMV8 | IL1B, SAR1A, HSPA1A | More | |
| Naftifine | hsa05140 | Leishmaniasis | 5.18E-04 | 6 | P14598, P42224, O60603, P25963, P29350, Q15080 | NCF1, STAT1, TLR2, NFKBIA, PTPN6, NCF4 | More | |
| Naftifine | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
| Naftifine | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | |
| Naftifine | hsa05146 | Amoebiasis | 6.83E-04 | 10 | P09341, P19875, P14778, P27930, P01375, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | |
| Naftifine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Naftifine | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | |
| Naftifine | hsa05163 | Human cytomegalovirus infection | 3.31E-02 | 7 | P0DP23, Q8NHW4, Q08828, P51828, P23458, P01584, Q13651 | CALM1, CCL4L2, ADCY1, ADCY7, JAK1, IL1B, IL10RA | More | |
| Naftifine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | |
| Naftifine | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | |
| Naftifine | hsa05169 | Epstein-Barr virus infection | 4.84E-03 | 10 | P13765, P01106, Q13547, O00463, P07948, Q13761, P24522, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, LYN, RUNX3, GADD45A, CD3E, CD3G, CD247 | More | |
| Naftifine | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
| Naftifine | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
| Naftifine | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
| Naftifine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Naftifine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Naftifine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | |
| Naftifine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
| Naftifine | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
| Naftifine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | |
| Naftifine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.61E-04 | 7 | P07766, P20963, P09693, P06239, Q04759, Q9HC35, P01730 | CD3E, CD247, CD3G, LCK, PRKCQ, EML4, CD4 | More | |
| Naftifine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Naftifine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Naftifine | hsa05323 | Rheumatoid arthritis | 2.00E-02 | 3 | Q13488, P10747, O60603 | TCIRG1, CD28, TLR2 | More | |
| Naftifine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Naftifine | hsa05332 | Graft-versus-host disease | 9.47E-05 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | |
| Naftifine | hsa05340 | Primary immunodeficiency | 1.31E-04 | 5 | P01730, P01732, P11912, P07766, P06239 | CD4, CD8A, CD79A, CD3E, LCK | More | |
| Naftifine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
| Naftifine | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | |
